1. Home
  2. BOXL vs VIVS Comparison

BOXL vs VIVS Comparison

Compare BOXL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boxlight Corporation

BOXL

Boxlight Corporation

HOLD

Current Price

$0.77

Market Cap

3.3M

ML Signal

HOLD

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.17

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOXL
VIVS
Founded
1985
2007
Country
United States
United States
Employees
N/A
9
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
BOXL
VIVS
Price
$0.77
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
68.1K
37.0K
Earning Date
04-16-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,743,612.00
N/A
Revenue This Year
$2.70
$42.38
Revenue Next Year
$5.00
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
26.37
N/A
52 Week Low
$0.50
$1.13
52 Week High
$10.15
$5.30

Technical Indicators

Market Signals
Indicator
BOXL
VIVS
Relative Strength Index (RSI) 38.51 30.77
Support Level $0.70 N/A
Resistance Level $0.95 $1.38
Average True Range (ATR) 0.07 0.07
MACD -0.00 -0.01
Stochastic Oscillator 23.53 6.77

Price Performance

Historical Comparison
BOXL
VIVS

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: